Breast-Microseed-Treatment

Breast Microseed Treatment is an outpatient radiation treatment for early-stage breast cancer with a 96% five-year survival rate

 

Breast cancer is the most common cancer affecting women and a staggering 250,000 new cases of breast cancer were reported in 2015 alone. Breast cancer occurs when a group of abnormal cells in the breast grow out of control at the expense of other tissues and have the ability to metastasize, or spread to other parts of the body. Breast cancer is very treatable when discovered early, and lumpectomy followed by radiation therapy ensures the highest survival rate.

Concure Oncology, a medical device and services provider, has recently launched Breast Microseed Treatment, a complete adjuvant radiation therapy in the form of a one-time, one-hour, procedure for women with early stage breast cancer. The Breast Microseed Treatment is performed in an outpatient setting and uses low-dose rate (LDR) bracytheraphy, or internal radiation. Seventy to ninety microseeds the size of a grain of rice are permanently implanted in the breast area where the cancer was removed so a therapeutic dose of radiation can be delivered from inside the breast. The seeds have a radiation half-life of 17 days and will eventually become inert.

Breast Microseed Treatment may be suitable for early-stage breast cancer patients who are candidates for partial breast irradiation, had their tumour removed by lumpectomy, >50 years old, have invasive ductal carcinoma or ductal carcinoma in situ, have no lymph node involvement, and no metastases. Clinical studies of this treatment over 10 years report similar efficacy to other post-lumpectomy radiation therapies, and a 5-year disease-free survival rate of 96.4%. Reported short-term side effects include redness, hardening of tissue, and skin peeling.

The Swedish Cancer Institute in Seattle, Washington, is the first cancer centre to offer Breast Microseed Treatment. Additional treatment sites in Pennsylvania, Georgia, and California will be added in the future as part of a U.S rollout plan by Concure Oncology.

 

 

 

Written By: Fiona Wong, PhD

Facebook Comments